Screener
Icahn Enterprises IEP Pharma — Liabilities And Stockholders Equity
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Icahn Enterprises in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The source filing: Icahn Enterprises’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-090605
| Line item | Investment | Energy | Automotive | Food Packaging | Real Estate | Home Fashion | Pharma | Holding Company | Consolidated |
|---|---|---|---|---|---|---|---|---|---|
| Accounts payable, accrued expenses and other liabilities | $752 | $1,578 | $711 | $110 | $28 | $38 | $63 | $75 | $3,355 |
| Securities sold, not yet purchased, at fair value | 1,000 | — | — | — | — | — | — | — | 1,000 |
| Debt | — | 1,783 | 25 | 129 | 1 | 25 | — | 4,426 | 6,389 |
| Total liabilities | 1,752 | 3,361 | 736 | 239 | 29 | 63 | 63 | 4,501 | 10,744 |
| Equity attributable to Icahn Enterprises | 1,978 | 575 | 554 | 178 | 1,128 | 148 | 153 | (3,705) | 1,009 |
| Equity attributable to non-controlling interests | 593 | 533 | — | 11 | — | — | — | — | 1,137 |
| Total equity | 2,571 | 1,108 | 554 | 189 | 1,128 | 148 | 153 | (3,705) | 2,146 |
| Total liabilities and equity | $4,323 | $4,469 | $1,290 | $428 | $1,157 | $211 | $216 | $796 | $12,890 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Icahn Enterprises's pharma — liabilities and stockholders equity?
- Icahn Enterprises (IEP) reported pharma — liabilities and stockholders equity of $216M in Q2 2026.
- How has Icahn Enterprises's pharma — liabilities and stockholders equity changed year-over-year?
- Icahn Enterprises's pharma — liabilities and stockholders equity decreased by 14.6% year-over-year, from $253M to $216M.
- What is the long-term trend for Icahn Enterprises's pharma — liabilities and stockholders equity?
- Over 4 years (2021 to 2025), Icahn Enterprises's pharma — liabilities and stockholders equity has grown at a -5.4% compound annual growth rate (CAGR), from $1.26B to $1.01B.
- What does pharma — liabilities and stockholders equity mean?
- The total sum of all liabilities and equity accounts for the pharmaceutical segment, which must equal the segment's total assets. This metric represents the total capital structure and financing sources utilized by the business. It is a fundamental balance sheet figure used to verify the accounting integrity of the segment's financial reporting.
Ask your AI about Icahn Enterprises's pharma — liabilities and stockholders equity.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude